Nurix Therapeutics (NRIX) vs Precigen (PGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Precigen (PGEN) has outperformed Nurix Therapeutics (NRIX) over the past year, gaining 8.5% versus a loss of 23.3%. Over five years, PGEN leads with a +9.1% price change compared with -57.3% for NRIX. Precigen is the larger company by market cap ($1.51 billion vs $1.40 billion), about 1.1 times the size.
On valuation, Nurix Therapeutics trades at a lower trailing P/E (5.3x vs 38.3x for Precigen). Nurix Therapeutics converts more of its revenue into profit, with a net margin of -314.9% versus -2588.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NRIX | PGEN |
|---|---|---|
| Share price | $12.85 | $4.21 |
| Market cap | $1.40B | $1.51B |
| 1-day change | -5.55% | +1.20% |
| YTD return | -32.26% | +0.72% |
| 1-year return | -23.33% | +8.51% |
| 5-year return | -57.25% | +9.07% |
| P/E ratio (TTM) | 5.29 | 38.27 |
| EPS (TTM) | $2.43 | $0.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $83.98M | $9.68M |
| Revenue growth (YoY) | +53.95% | +146.73% |
| Net income (latest FY) | $-264.46M | $-250.64M |
| Operating margin | -340.16% | -1141.13% |
| Net margin | -314.90% | -2588.21% |
| 52-week high | $28.23 | $8.98 |
| 52-week low | $12.83 | $3.04 |
| Distance from 52-week high | -54.50% | -53.12% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +160.80% | +224.70% |
| Average volume | 2.47M | 5.68M |
| Shares outstanding | 109.25M | 358.55M |
| Employees | 317 | 160 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PGEN has outperformed NRIX by 31.8 percentage points over the past year.
- Precigen trades at a higher earnings multiple (38.3x vs 5.3x trailing P/E).
- Nurix Therapeutics is more profitable, keeping -314.9 cents of every revenue dollar as net income versus -2588.2 cents for Precigen.
- Precigen grew revenue faster in its latest fiscal year (+146.73% vs +53.95%).
About Nurix Therapeutics
NRIX stock →Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, which is in Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 317 employees
About Precigen
PGEN stock →Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 160 employees
NRIX vs PGEN FAQ
Which is bigger, Nurix Therapeutics or Precigen?
Precigen (PGEN) is larger, with a market capitalization of $1.51B compared with $1.40B for Nurix Therapeutics (NRIX).
Which stock has performed better over the past year, NRIX or PGEN?
PGEN returned +8.51% over the past 12 months, compared with -23.33% for NRIX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, NRIX or PGEN?
NRIX has the lower trailing P/E at 5.3, versus 38.3 for PGEN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Nurix Therapeutics and Precigen in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.